Compare · ABT vs ABVX
ABT vs ABVX
Side-by-side comparison of Abbott Laboratories (ABT) and Abivax SA (ABVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ABVX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $180.95B, about 23.3x ABVX ($7.77B).
- Over the past year, ABT is down 14.2% and ABVX is down 12.4% - ABVX leads by 1.8 points.
- ABT has hit the wire 9 times in the past 4 weeks while ABVX has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 17 for ABVX).
- Company
- Abbott Laboratories
- Abivax SA
- Price
- $106.24+1.61%
- $86.61-2.78%
- Market cap
- $180.95B
- $7.77B
- 1M return
- +9.87%
- -8.98%
- 1Y return
- -14.21%
- -12.42%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 17
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
- SEC Form 8-K filed by Abbott Laboratories
- SEC Form 8-K filed by Abbott Laboratories
- Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
- Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
Latest ABVX
- Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
- SEC Form F-6EF filed by Abivax SA
- SEC Form 6-K filed by Abivax SA
- Abivax Presents Business Updates and First Half 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA
- Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
- Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
- Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA
- Abivax Announces Closing of $920 Million Public Offering
- SEC Form 6-K filed by Abivax SA